Teachers Retirement System of The State of Kentucky Decreases Stock Position in PRA Health Sciences, Inc. (NASDAQ:PRAH)

Teachers Retirement System of The State of Kentucky cut its position in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 0.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 59,098 shares of the medical research company’s stock after selling 500 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in PRA Health Sciences were worth $7,413,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in shares of PRA Health Sciences in the fourth quarter valued at $61,000. Panagora Asset Management Inc. boosted its stake in shares of PRA Health Sciences by 14.1% in the fourth quarter. Panagora Asset Management Inc. now owns 1,208 shares of the medical research company’s stock valued at $152,000 after purchasing an additional 149 shares during the period. Veriti Management LLC purchased a new position in shares of PRA Health Sciences in the fourth quarter valued at $258,000. Cetera Advisor Networks LLC purchased a new position in shares of PRA Health Sciences in the fourth quarter valued at $259,000. Finally, IBM Retirement Fund boosted its stake in PRA Health Sciences by 15.0% during the 4th quarter. IBM Retirement Fund now owns 2,358 shares of the medical research company’s stock valued at $296,000 after acquiring an additional 307 shares during the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

In related news, CAO Christopher L. Gaenzle sold 3,136 shares of the firm’s stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $130.04, for a total value of $407,805.44. Following the sale, the chief accounting officer now owns 34,500 shares of the company’s stock, valued at approximately $4,486,380. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.30% of the company’s stock.

Shares of NASDAQ PRAH opened at $157.00 on Thursday. The company has a market cap of $10.13 billion, a price-to-earnings ratio of 45.91, a price-to-earnings-growth ratio of 2.26 and a beta of 1.24. PRA Health Sciences, Inc. has a 12-month low of $79.15 and a 12-month high of $158.26. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 0.95. The stock’s 50 day simple moving average is $145.56 and its 200 day simple moving average is $123.19.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings results on Wednesday, February 24th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.31. PRA Health Sciences had a return on equity of 22.21% and a net margin of 7.09%. As a group, equities analysts forecast that PRA Health Sciences, Inc. will post 3.85 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of PRA Health Sciences from a “sell” rating to a “hold” rating and set a $160.00 target price for the company in a research report on Tuesday, March 30th. Mizuho boosted their price objective on PRA Health Sciences from $110.00 to $155.00 in a report on Friday, March 19th. Jefferies Financial Group downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Thursday, February 25th. Robert W. Baird increased their target price on PRA Health Sciences from $130.00 to $145.00 and gave the stock an “outperform” rating in a report on Thursday, January 21st. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of PRA Health Sciences in a report on Monday, March 15th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $122.89.

PRA Health Sciences Profile

PRA Health Sciences, Inc engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services.

See Also: Overbought

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.